| Literature DB >> 22740850 |
Yi Wang1, Jun-Ichiro Ikeda, Nur Rahadiani, Suhana Mamat, Yutaka Ueda, Tian Tian, Takayuki Enomoto, Tadashi Kimura, Katsuyuki Aozasa, Eiichi Morii.
Abstract
Elongator protein 3 (ELP3), the catalytic subunit of the elongator complex of RNA polymerase II, is involved in various functions, including transcriptional elongation, chromatin modification and cytoskeletal regulation. In this study, ELP3 expression was immunohistochemically examined in normal uterus tissue and uterine endometrioid adenocarcinoma tissue. ELP3 was abundantly expressed in both the proliferative and secretory phases of the endometrial cycle. However, ELP3 expression levels varied among cases of endometrioid adenocarcinoma. In patients with endometrioid adenocarcinoma, a low ELP3 expression was correlated to a high T-factor (p=0.036), tumor stage (p=0.001), lymph node metastasis (p<0.001), resistance to chemotherapy (p=0.045), recurrence (p=0.004) and poor prognosis (p=0.003). Univariate and multivariate analyses revealed that a low ELP3 expression was an independent factor for poor prognosis. In conclusion, this is the first study to examine the clinical implications of ELP3 expression in cancer.Entities:
Year: 2011 PMID: 22740850 PMCID: PMC3362337 DOI: 10.3892/ol.2011.428
Source DB: PubMed Journal: Oncol Lett ISSN: 1792-1074 Impact factor: 2.967